DNTH

SEC source: 0000899243-20-035052 · doc4.xml · derivative · entry 1

Lawton Alison Frances · CIK 0001542650 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,377

Underlying: Common Stock · 36,377 shares

Expires 2030-12-21

F1 · derivative.exercise_date: This option shall vest and become exercisable over three years, with 33% of this option vesting on December 22, 2021, and the remainder vesting in 24 equal monthly installments thereafter.

SEC source: 0000899243-20-030392 · doc4.xml · derivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,000

Underlying: Common Stock · 435,000 shares

Expires 2030-11-01

F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on November 2, 2021, and the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0000899243-20-025332 · doc4.xml · derivative · entry 1

Olson Lisa · CIK 0001824009 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-09-13

F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.

SEC source: 0001209191-20-039768 · doc4.xml · nonDerivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,250,000

F1 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Dr. Booth is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-015808 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015805 · doc4.xml · derivative · entry 1

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015801 · doc4.xml · derivative · entry 1

RONNEBERG AMY L · CIK 0001380292 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015799 · doc4.xml · derivative · entry 1

BONNEY MICHAEL W · CIK 0001219016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015798 · doc4.xml · derivative · entry 1

Booth Bruce · CIK 0001451612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-20-015797 · doc4.xml · derivative · entry 1

McGeorge Anne · CIK 0001779934 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015796 · doc4.xml · derivative · entry 1

Daniel Thomas O · CIK 0001538894 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015790 · doc4.xml · derivative · entry 1

Scadden David · CIK 0001707715 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-015789 · doc4.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-20-010847 · doc4.xml · derivative · entry 1

DAVIS JOHN C. JR · CIK 0001741287 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-04-13

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on April 14, 2020.

SEC source: 0000899243-20-004313 · doc4.xml · derivative · entry 1

ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

SEC source: 0000899243-20-004321 · doc4.xml · derivative · entry 1

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,000

Underlying: Common Stock · 104,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

SEC source: 0000899243-20-004316 · doc4.xml · derivative · entry 1

Ryan Jason · CIK 0001585017 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

SEC source: 0000899243-20-004308 · doc4.xml · derivative · entry 1

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

SEC source: 0000899243-20-004301 · doc4.xml · derivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2030-02-09

F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

SEC source: 0001562180-20-000327 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,212

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-20-000119 · primarydocument.xml · derivative · entry 3

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,831

Underlying: Common Stock · 11,294 shares

Expires 2028-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

SEC source: 0001562180-20-000119 · primarydocument.xml · nonDerivative · entry 2

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,304

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-20-000119 · primarydocument.xml · nonDerivative · entry 1

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-20-000118 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,412

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

SEC source: 0001562180-19-006266 · primarydocument.xml · nonDerivative · entry 1

ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,786

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006265 · primarydocument.xml · nonDerivative · entry 1

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,009

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 8

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,856

Underlying: Common Stock · 820 shares

Expires 2028-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

F7 · derivative.exercise_date: This option vests and becomes exercisable in 16 equal quarterly installments beginning on January 1, 2018.

SEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 5

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,010

F2 · kind: This trade is pursuant to an active 10b5-1 plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

F5 · balance_after: Balance has been updated to reflect the shares acquired and sold on the form 4 filed 12/26/2019.

SEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 4

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

SEC source: 0001562180-19-006252 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,212

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006260 · primarydocument.xml · nonDerivative · entry 1

ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,249

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006261 · primarydocument.xml · nonDerivative · entry 1

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,911

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 7

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,676

Underlying: Common Stock · 9 shares

Expires 2028-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

F7 · derivative.exercise_date: This option vests and becomes exercisable in 16 equal quarterly installments beginning on January 1, 2018.

SEC source: 0001562180-19-006291 · primarydocument.xml · derivative · entry 6

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,342

Underlying: Common Stock · 4,172 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

F6 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments beginning on the date of effectiveness of the Issuer's Registration Statement on Form S-1.

SEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 3

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,092

F2 · kind: This trade is pursuant to an active 10b5-1 plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 2

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,273

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

SEC source: 0001562180-19-006291 · primarydocument.xml · nonDerivative · entry 1

ZDRAVESKI ZORAN · CIK 0001741285 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · acquired: Shares were not previously reported on the form 4 filed 12/26/2019 as an option exercise.

SEC source: 0001562180-19-006221 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,109

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.10 to $15.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006220 · primarydocument.xml · derivative · entry 5

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,125

Underlying: Common Stock · 114 shares

Expires 2028-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

SEC source: 0001562180-19-006220 · primarydocument.xml · derivative · entry 4

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,239

Underlying: Common Stock · 805 shares

Expires 2028-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

SEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 3

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,304

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

SEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 2

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-006220 · primarydocument.xml · nonDerivative · entry 1

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,418

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-006009 · primarydocument.xml · derivative · entry 6

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,044

Underlying: Common Stock · 17,055 shares

Expires 2028-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

SEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 4

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,304

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 3

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,359

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-006078 · primarydocument.xml · nonDerivative · entry 1

GARDNER JASON · CIK 0001741286 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,820

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

SEC source: 0001562180-19-006009 · primarydocument.xml · derivative · entry 5

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,099

Underlying: Common Stock · 4,614 shares

Expires 2028-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

SEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 2

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,304

F1 · kind: This trade is pursuant to an active 10b5-1 plan.

SEC source: 0001562180-19-006009 · primarydocument.xml · nonDerivative · entry 1

DAVIS JOHN C. JR · CIK 0001741287 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.